Altos Labs was founded in 2021 by Hans Bishop and Richard Klausner. Altos Labs has not publicly endorsed a plan to participate in an IPO.
Altos Labs is a biotech company with a focus on cellular rejuvenation programming to restore cell health and resilience. Per Forge data, the most recent funding for Altos Labs was in January 2021. Their total funding raised is $3 billion. Key investors include ARCH Venture Partners.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Altos Labs is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Altos Labs pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Altos Labs is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
Jeff Bezos invested in Altos Labs in 2022.
Altos Labs is a new biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine.
The CEO of Altos Labs is Hal Barron.